Emcure Pharmaceuticals posted a 16.7% year-on-year rise in Q4FY26 revenue at ₹2,470 crore, driven by strong international performance.
Adjusted PAT grew 36% YoY to ₹279 crore, while reported PAT increased 23.6% to ₹244 crore. EBITDA rose 24.5% to ₹485 crore, with margins improving to 19.7%.
International sales surged 25.7% YoY to ₹1,493 crore, while domestic sales grew modestly by 5.2% to ₹977 crore.
Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, “In FY26, the first year of our five-year strategic plan, Emcure delivered strong financial performance with over US$1 billion in revenue and 16.6% growth. International markets demonstrated robust momentum while our domestic business recorded steady growth. We delivered ~41% adjusted PAT growth in the year. We strategically expanded through in-licensing, Zuventus minority buyout and bolt-on acquisitions in the UK and Canada. Our R&D pipeline in complex injectables and biosimilars remains a key driver of future value. Our priorities remain clear – to deliver sustainable, above-industry growth and consistent margin expansion, while continuing to build sustainable long-term value for all stakeholders.”
